Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Clover Health Launches New Clinical Program Targeting Chronic Kidney Disease in Partnership with Cricket Health
09 déc. 2021 09h00 HE
|
Clover Health Investments, Corp.
The Clover Assistant synthesizes health data and surfaces personalized clinical recommendations to physicians to drive earlier disease detection and interventionSpecialty kidney services now...
Hematuria Treatment Market Size ($1,103.61Mn by 2028) Led by Urinary Tract Infections (17.31% Market Share in 2020) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 13h45 HE
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Hematuria Treatment Market: Key InsightsAccording to our new research study on Hematuria Treatment Market Size and Forecast to 2028 - COVID-19 Impact and...
Global Renal Care Management Market Research Report 2021: Value-based Renal Care to Provide a Strong Platform for Payer-driven Innovations and Major Industry Disruptions
29 sept. 2021 07h13 HE
|
Research and Markets
Dublin, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The "Global Renal Care Management Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The global prevalence of CKD is...
ARDX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
26 sept. 2021 15h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 26, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important September 28 Deadline in Securities Class Action – ARDX
17 sept. 2021 19h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
27 août 2021 17h45 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ARDX INVESTOR NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
19 août 2021 16h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ARDX INVESTOR NEWS: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ARDX
13 août 2021 18h15 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ardelyx, Inc. (NASDAQ: ARDX) between August 6, 2020 and...
ROSEN, A RESPECTED AND LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ARDX
03 août 2021 15h45 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
16 juin 2021 08h00 HE
|
KBP BioSciences
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2 mm Hg with reduced hyperkalemia risk in the phase 2b studyArticle...